SGMO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sangamo Therapeutics Inc (SGMO) is not a strong buy for a beginner investor with a long-term horizon at this time. While the company has shown significant revenue growth in its latest quarter, its financials remain weak with negative net income and EPS. The technical indicators and trading trends do not suggest a clear upward momentum, and there are no significant positive catalysts or trading signals to support immediate investment. The stock may be better suited for speculative or short-term trading rather than a long-term investment.
The MACD is slightly positive and expanding, indicating mild bullish momentum. However, the RSI is neutral at 47.404, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point of 0.27, with resistance at 0.301 and support at 0.239, suggesting limited immediate upside potential.
Revenue increased by 88.43% YoY in 2025/Q4, indicating strong top-line growth. Gross margin remains at 100%, showing operational efficiency.
The company remains unprofitable with a net loss of -$37.42M in the latest quarter. No recent news, analyst upgrades, or significant insider or hedge fund activity to drive the stock higher. Congress trading data is also absent.
In 2025/Q4, revenue grew by 88.43% YoY to $14.23M. However, net income remains negative at -$37.42M, despite improving by 59.94% YoY. EPS is stagnant at -0.11 YoY, and the company remains in a loss-making position.
No recent analyst rating or price target updates are available for SGMO.
